Clinical trials: Subcutaneous Injection
Hypoparathyroidism
Monocentric Study on the Use of Teriparatide in Children With hypoparathyroïdism
Pediatric hypoparathyroidism is an orphan disease. Conventional management combines native and active vitamin D, calcium supplementation and sometimes phosphate binders, with the risk of long term hypercalciuria, nephrocalcinosis…
- Trial name
- FOR-HYPO (NCT04126941)
- Testing
- Serum calcium concentrations results
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Hospices Civils de Lyon
Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus
The main purpose of this study is to assess the safety and tolerability of multiple subcutaneous injections of HRS9531 in patients with type 2 diabetes mellitus who have suboptimal glycaemic control after conventional lifestyle…
- Trial name
- NCT05516966
- Testing
- HRS9531, Dulaglutide Injection
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Low Back Pain
Subcutaneous Sterile Water Injection for Relief of Low Back Pain
To compare the effect of subcutenous sterile water injection technique with the subcutaneous saline injection technique in the degree and duration of low back pain-relieving during childbirth
- Trial name
- NCT02813330
- Testing
- Subcutaneous sterile water injection, saline injection
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Woman's Health University Hospital, Egypt
Healthy Volunteers
A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants
The purpose of this study is to compare the PK of single dose of vedolizumab SC 108 milligram (mg) administered as PFS vs investigational device.
- Trial name
- NCT03948581
- Testing
- Vedolizumab SC
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Takeda
Spondylitis, Ankylosing
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis
The purpose of this study is to provide 16-week efficacy, safety and tolerability data versus placebo to support the use of secukinumab 150 mg by subcutaneous (s.c.) self-administration with or without a loading regimen and…
- Trial name
- MEASURE4 (NCT02159053)
- Testing
- Secukinumab
- Where
- 90 sites in United States, Australia and 17 more
- Volunteers
- 350 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus Type 1
Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes
This study is to compare metabolic control, treatment satisfaction, and quality of life during continuous subcutaneous insulin infusion (CSII ) therapy with a new insulin pump system with multiple daily injections (MDI) therapy.
- Trial name
- Insight Kids (NCT02403375)
- Testing
- Accu-Chek Insight Pump System
- Where
- 9 sites in Austria, Germany and 1 more
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Introducing a Single IV Abatacept Treatment in RA Patients Currently Receiving Weekly SC Abatacept to Simulate a Holiday
RA (rheumatoid arthritis) patients effectively treated weekly with SC (subcutaneous) Abatacept will be switched to IV (intravenous) Abatacept and restarted with SC Abatacept four after IV application.
- Trial name
- A-BREAK (NCT01846975)
- Testing
- IV Abatacept
- Where
- Switzerland
- Volunteers
- 49 people
- Sponsor
- Rüdiger B. Müller
Kaposi Sarcoma, HIV Infections
An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
To determine the safety of escalating IV doses of Tc 99m tilmanocept in HIV (human immunodeficiency virus) subjects with confirmed KS and to compare results obtained from subcutaneous and IV administrations of Tc 99m tilmanocept…
- Trial name
- NCT03157167
- Testing
- Tc99m-tilmanocept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Navidea Biopharmaceuticals
Subcutaneous Fat
A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
The Stage 1 of this phase 2 study is an open-label single ascending dose (SAD) study. The primary objectives are to evaluate the safety and tolerability of injection lipolysis with CBL-514.
- Trial name
- NCT04575467
- Testing
- CBL-514
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Uveitis
Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis
This study will examine the safety and effectiveness of a monoclonal antibody called daclizumab in treating uveitis, an eye inflammation.
- Trial name
- NCT00043667
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Eye Institute (NEI)
Psoriasis
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin.
- Trial name
- OptIMMize-1 (NCT04435600)
- Testing
- Risankizumab, Ustekinumab
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 139 people
- Sponsor
- AbbVie
OVARIAN STIMULATION, Infertility
Pharmacokinetics of FSH and hCG After a Single Subcutaneous Injection of Gonadotropins-IBSA
The objectives of this study is to evaluate the PK and the dose-proportionality of FSH and HCG following a single dose of Gonadotropins-IBSA, administered subcutaneously.
- Trial name
- NCT06781957
- Testing
- Gonadotropins Subcutaneos
- Where
- Canada
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- IBSA Institut Biochimique SA
Coronary Disease, Myocardial Infarction
A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction
RUC-4 is a novel, promising and fast acting (5-15 minutes) αIIbβ3 receptor antagonist with a high-grade inhibition of platelet aggregation (≥80%) shortly after subcutaneous administration.
- Conditions
- Coronary Disease, Myocardial Infarction, Heart Diseases, Vascular Diseases
- Trial name
- CEL-02 (NCT04284995)
- Testing
- RUC-4 Compound
- Where
- Netherlands
- Volunteers
- 27 people
- Sponsor
- CeleCor Therapeutics
Healthy
A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants
The purpose of this study is to evaluate the pharmacokinetic (PK) and bioequivalence (BE) of ustekinumab administered by a single subcutaneous (SC) injection with Device 1 or Device 2 in healthy participants.
- Trial name
- NCT04816513
- Testing
- Ustekinumab
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Volunteers
Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-2173 in Healthy Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics and immunogenicity of a single dose of SHR-2173 by subcutaneous injection.
- Trial name
- NCT06995001
- Testing
- SHR-2173
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Postoperative Analgesia
Pharmacokinetic and Safety Study of HYR-PB21 vs Bupivacaine Hydrochloric Acid in Healthy Participants
This is a Phase I, randomized, single-blind, active-controlled, single-dose, parallel-group study to evaluate the safety and pharmacokinetic (PK) profile of HYR-PB21, a pamoate-formulated bupivacaine injectable, in healthy adult…
- Trial name
- NCT07717086
- Testing
- HYR-PB21， 100 mg, HYR-PB21， 200 mg, HYR-PB21， 400 mg
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Fruithy Holdings Limited
HIV Infections
A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone
To compare two different routes of intermittently administered rhIL-2 with a highly active antiretroviral regimen (HAART) to HAART alone.
- Trial name
- NCT00000870
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 20 sites in United States
- Volunteers
- 200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Primary Membranous Nephropathy
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
This Phase I Clinical Study assessed the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the…
- Trial name
- NCT05668403
- Testing
- B007
- Where
- 6 sites in China
- Volunteers
- 52 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Alzheimer's Disease
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients
Objective of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary pharmacodynamic effects of multiple doses of Gantenerumab in subject with mild to moderate AD.
- Trial name
- NCT01656525
- Testing
- Gantenerumab
- Where
- 5 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Chugai Pharmaceutical
Primary Immunodeficiency
ASIS for GAMMAGARD in Primary Immunodeficiency
ASIS Corporation (ASIS) has developed the only automatic injection system for delivery of injectable products to it's optimum/right spot, just outside of the fascia, which exists subdermally (between the skin and muscle).
- Trial name
- ASISinPI (NCT02123615)
- Testing
- Gadolinium For abdomen, Gadolinium For lower back, Efficacy of Gammagard subcutaneously at Week 12
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- ASIS Corporation